Tempest Therapeutics, Inc. financial data

Symbol
TPST on Nasdaq
Location
2000 Sierra Point Parkway, Suite 400, Brisbane, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 191 % -31.8%
Debt-to-equity 156 % -0.31%
Return On Equity -335 % -66.5%
Return On Assets -131 % -66.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.44M shares -82.4%
Common Stock, Shares, Outstanding 4.44M shares -81.9%
Entity Public Float 53.6M USD +235%
Common Stock, Value, Issued 4K USD -83.3%
Weighted Average Number of Shares Outstanding, Basic 3.8M shares +119%
Weighted Average Number of Shares Outstanding, Diluted 3.8M shares +119%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13.6M USD +3.78%
Operating Income (Loss) -43.4M USD -37%
Nonoperating Income (Expense) 273K USD +700%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -43.1M USD -35.8%
Earnings Per Share, Basic 3 USD/shares +62.5%
Earnings Per Share, Diluted 3 USD/shares +62.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.3M USD -54.1%
Other Assets, Current 482K USD +1277%
Assets, Current 15.1M USD -52.1%
Property, Plant and Equipment, Net 748K USD -26.2%
Operating Lease, Right-of-Use Asset 8.1M USD -11.5%
Other Assets, Noncurrent 529K USD +18.1%
Assets 24.5M USD -41.9%
Accounts Payable, Current 4.72M USD +248%
Employee-related Liabilities, Current 101K USD -91.1%
Accrued Liabilities, Current 1.22M USD -48.7%
Liabilities, Current 7.14M USD -51%
Operating Lease, Liability, Noncurrent 7.56M USD -12.7%
Liabilities 14.7M USD -41.7%
Retained Earnings (Accumulated Deficit) -226M USD -23.6%
Stockholders' Equity Attributable to Parent 9.78M USD -42.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9.78M USD -42.2%
Liabilities and Equity 24.5M USD -41.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.04M USD -11.8%
Net Cash Provided by (Used in) Financing Activities -721K USD -260%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.44M shares -81.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.31M USD -45.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.7M USD -53.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 148K USD -54.6%
Deferred Tax Assets, Valuation Allowance 177M USD +7.38%
Deferred Tax Assets, Gross 179M USD +6.99%
Depreciation 281K USD -32.5%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Property, Plant and Equipment, Gross 2.2M USD -3.46%
Operating Lease, Liability, Current 1.1M USD +17.5%
Deferred Tax Assets, Operating Loss Carryforwards 144M USD +5.11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 5.24M USD +6.42%
Additional Paid in Capital 236M USD +18%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.54M USD -14.6%
Share-based Payment Arrangement, Expense 5.15M USD +19.7%
Interest Expense 1.49M USD -1.97%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares